Double-blind crossover trial (n=12) investigating repeated oral psilocybin (two sessions; low 0.0143 mg/kg or 1 mg and high 0.143 mg/kg or 10 mg) versus placebo for post-traumatic headache.
This randomised, double-blind, crossover study evaluates oral psilocybin (low and high dose) versus placebo in participants with post-traumatic headache over two test days separated by approximately 14 days.
Participants maintain a headache diary before, during and after treatments to record frequency, intensity and associated symptoms; blood samples are collected to measure inflammatory peptides.
Randomised crossover sequences comparing placebo, low-dose and high-dose oral psilocybin across two test days ~14 days apart.
Placebo oral capsule (microcrystalline cellulose).
Low dose: 0.0143 mg/kg (weight-based) or 1 mg fixed-dose option.
High dose: 0.143 mg/kg (weight-based) or 10 mg fixed-dose option.